Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 47 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate CancerCompletedNCT00427999Phase 2Results posted
• AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver CancerTerminatedNCT00427973Phase 2Results posted
• AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2Results posted
• An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast CancerCompletedNCT00425854Phase 2Results posted
• Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00425386Phase 2Results posted
• Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaCompletedNCT00424515Phase 2Results posted
• Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)CompletedNCT00424385Phase 1Results posted
• Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After SurgeryCompletedNCT00424255Phase 3Results posted
• Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00423735Phase 2Results posted
• Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell CarcinomaCompletedNCT00423332Phase 2Results posted
• Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast CancerCompletedNCT00422903Phase 2Results posted
• Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompletedNCT00418886Phase 3Results posted
• A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast CancerTerminatedNCT00417885Phase 1/2Results posted
• Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung CancerTerminatedNCT00417248Phase 1/2Results posted
• TALL-104 and Gleevec in Chronic Myelogenous Leukemia PatientsTerminatedNCT00415909Phase 2Results posted
• Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate CancerCompletedNCT00414388Phase 1/2Results posted
• Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid ArthritisCompletedNCT00413699Phase 3Results posted
• Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid ArthritisCompletedNCT00413660Phase 2Results posted
• A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell CancerTerminatedNCT00412217Phase 3Results posted
• BATTLE Program: Sorafenib in Patients With NSCLCCompletedNCT00411671Phase 2Results posted
• BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00411632Phase 2Results posted
• Efficacy and Safety of Sunitinib in Metastatic Gastric CancerCompletedNCT00411151Phase 2Results posted
• AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung CancerCompletedNCT00410904Phase 2Results posted
• Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00410826Phase 2Results posted
• S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the BoneCompletedNCT00410813Phase 2Results posted
• An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompletedNCT00410761Phase 3Results posted
• BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLCCompletedNCT00410189Phase 2Results posted
• BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLCCompletedNCT00410059Phase 2Results posted
• Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney CancerCompletedNCT00408902Phase 2Results posted
• Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung CancerCompletedNCT00408499Phase 1/2Results posted
• Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00408460Phase 2Results posted
• ZD6474 (ZACTIMA™) Phase III Study in EGFR FailuresCompletedNCT00404924Phase 3Results posted
• Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast CancerCompletedNCT00404066Phase 2Results posted
• Malignant Pleural Effusion With ZD6474TerminatedNCT00402896Phase 2Results posted
• Erlotinib Prevention of Oral Cancer (EPOC)CompletedNCT00402779Phase 3Results posted
• Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue SarcomaCompletedNCT00400569Phase 2Results posted
• Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal CancerCompletedNCT00399035Phase 3Results posted
• A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast CancerCompletedNCT00398567Phase 1/2Results posted
• Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00398112Phase 2Results posted
• AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal CancerTerminatedNCT00397878Phase 2Results posted
• Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the UrotheliumCompletedNCT00397488Phase 2Results posted
• A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid TumorsCompletedNCT00397046Phase 1Results posted
• Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast CancerCompletedNCT00393939Phase 3Results posted
• Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial CarcinomaTerminatedNCT00393796Phase 2Results posted
• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal CancerCompletedNCT00393068Phase 2Results posted
• Treatment of Head & Neck Cancer With Chemotherapy and RadiationCompletedNCT00392704Phase 2Results posted
• Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell LymphomaCompletedNCT00392496Phase 2Results posted
• Sunitinib in Treating Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT00392444Phase 2Results posted
• Treatment of Adult Ph+ LAL With BMS-354825CompletedNCT00391989Phase 2Results posted
• Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the LungTerminatedNCT00391586Phase 2Results posted
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
• Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian CancerCompletedNCT00390611Phase 2Results posted
• Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone MetastasesCompletedNCT00390468Phase 2Results posted
• Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsCompletedNCT00390429Phase 1/2Results posted
• Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerCompletedNCT00390325Phase 2Results posted
• Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By SurgeryCompletedNCT00389974Phase 2Results posted
• Study Of AG-013736 In Patients With 131I-Refractory Thyroid CancerCompletedNCT00389441Phase 2Results posted
• Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00388037Phase 2Results posted
• Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaTerminatedNCT00387894Phase 2Results posted
• Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell CancerCompletedNCT00387764Phase 3Results posted
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00387751Phase 2Results posted
• Sunitinib in Treating Patients With Idiopathic MyelofibrosisTerminatedNCT00387426Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00387335Phase 2Results posted
• Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck CancerCompletedNCT00387127Phase 2Results posted
• Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung CancerCompletedNCT00385996Phase 2Results posted
• Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate CancerCompletedNCT00385580Phase 2Results posted
• The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).CompletedNCT00385203Phase 2Results posted
• First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOXCompletedNCT00384176Phase 2/3Results posted
• Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryCompletedNCT00381641Phase 2Results posted
• Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder CancerCompletedNCT00380029Phase 2Results posted
• Tandutinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT00379080Phase 1/2Results posted
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
• Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT00376948Phase 2Results posted
• A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell CancerCompletedNCT00375674Phase 3Results posted
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerCompletedNCT00374322Phase 3Results posted
• A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsCompletedNCT00373425Phase 3Results posted
• A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast CancerCompletedNCT00373256Phase 3Results posted
• A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And CapecitabineTerminatedNCT00373113Phase 3Results posted
• Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain MetastasesCompletedNCT00372775Phase 2Results posted
• Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsTerminatedNCT00372567Phase 3Results posted
• A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck CancerCompletedNCT00371566Phase 2Results posted
• Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast CancerCompletedNCT00371345Phase 2Results posted
• A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerCompletedNCT00371254Phase 2Results posted
• A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell CarcinomaCompletedNCT00369512Phase 2Results posted
• Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung CancerCompletedNCT00367679Phase 2Results posted
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung CancerCompletedNCT00367601Phase 2Results posted
• Gemcitabine, Bevacizumab and Erlotinib in Pancreatic CancerCompletedNCT00366457Phase 2Results posted
• Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerCompletedNCT00365391Phase 2Results posted
• Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With GemcitabineCompletedNCT00365144Phase 2Results posted
• Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior ChemotherapyCompletedNCT00364351Phase 3Results posted
• Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)CompletedNCT00364286Phase 2Results posted
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyTerminatedNCT00362466Phase 3Results posted
• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteCompletedNCT00360360Phase 2Results posted
• A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerCompletedNCT00358956Phase 2Results posted
• Iressa Follow-up TrialCompletedNCT00357734Phase 3Results posted
• Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCompletedNCT00356889Phase 2Results posted
• Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast CancerCompletedNCT00356811Phase 2Results posted
• A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerCompletedNCT00355238Phase 2Results posted
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2Results posted
• Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaCompletedNCT00353301Phase 2Results posted

← Tyrosine Kinase Inhibitors overview